Published in Cancer Res on October 01, 2004
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol (2009) 6.43
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res (2006) 2.56
Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res (2009) 2.42
Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell (2009) 2.14
Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro Oncol (2009) 2.04
Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol (2008) 1.84
TWIST is expressed in human gliomas and promotes invasion. Neoplasia (2005) 1.70
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol (2007) 1.59
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res (2008) 1.52
Molecular classification of low-grade diffuse gliomas. Am J Pathol (2010) 1.51
Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol (2009) 1.48
A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol (2012) 1.44
PDGF and PDGF receptors in glioma. Ups J Med Sci (2012) 1.43
A unique four-hub protein cluster associates to glioblastoma progression. PLoS One (2014) 1.42
Adult cerebellar glioblastoma: understanding survival and prognostic factors using a population-based database from 1973 to 2009. World Neurosurg (2013) 1.41
The pathobiology of glioma tumors. Annu Rev Pathol (2010) 1.40
Mechanisms of glioma-associated neovascularization. Am J Pathol (2012) 1.39
Multiscale agent-based cancer modeling. J Math Biol (2008) 1.37
Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol (2005) 1.34
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol (2010) 1.33
IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep (2013) 1.32
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol (2010) 1.31
Recent advances in the molecular understanding of glioblastoma. J Neurooncol (2012) 1.29
PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ (2010) 1.28
Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol (2009) 1.27
NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother (2010) 1.25
Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer (2011) 1.25
Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer (2008) 1.24
Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int (2012) 1.23
Identification of cell surface glycoprotein markers for glioblastoma-derived stem-like cells using a lectin microarray and LC-MS/MS approach. J Proteome Res (2010) 1.23
Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev (2014) 1.22
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets (2012) 1.21
Increasing rates of brain tumours in the Swedish national inpatient register and the causes of death register. Int J Environ Res Public Health (2015) 1.21
Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clin Med Oncol (2009) 1.21
Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol (2009) 1.20
Differential palliative care issues in patients with primary and secondary brain tumours. Support Care Cancer (2009) 1.18
Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int (2014) 1.18
Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol (2009) 1.17
Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol (2014) 1.17
CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteomics (2011) 1.16
Roles of BCCIP in chromosome stability and cytokinesis. Oncogene (2007) 1.16
Case-control study of the association between malignant brain tumours diagnosed between 2007 and 2009 and mobile and cordless phone use. Int J Oncol (2013) 1.15
Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med (Berl) (2005) 1.14
Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest (2012) 1.12
Expression and clinical significance of EGFL7 in malignant glioma. J Cancer Res Clin Oncol (2010) 1.11
Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation. Cancer Res (2010) 1.11
Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev (2010) 1.11
The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS One (2011) 1.11
Prediction of Associations between microRNAs and Gene Expression in Glioma Biology. PLoS One (2011) 1.10
Vascular gene expression patterns are conserved in primary and metastatic brain tumors. J Neurooncol (2010) 1.10
Glioblastoma multiforme outcomes of 107 patients treated in two Singapore institutions. Singapore Med J (2016) 1.10
Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One (2011) 1.10
Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget (2012) 1.09
Moving toward molecular classification of diffuse gliomas in adults. Neurology (2012) 1.08
Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol (2012) 1.08
Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol (2007) 1.07
Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol (2015) 1.06
Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell Cycle (2011) 1.06
Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). Exp Ther Med (2011) 1.05
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol Cancer (2010) 1.05
A simplified approach for the molecular classification of glioblastomas. PLoS One (2012) 1.05
MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma. PLoS One (2012) 1.05
Notch signaling in glioblastoma: a developmental drug target? BMC Med (2010) 1.04
Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. BMC Med Genomics (2011) 1.04
GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity. Neuro Oncol (2014) 1.04
A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors. PLoS One (2009) 1.03
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol (2009) 1.03
Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype. PLoS One (2012) 1.03
Method for lipidomic analysis: p53 expression modulation of sulfatide, ganglioside, and phospholipid composition of U87 MG glioblastoma cells. Anal Chem (2007) 1.02
Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. Neuro Oncol (2009) 1.02
Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc Natl Acad Sci U S A (2007) 1.02
Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch (2008) 1.01
PDCD4 gene silencing in gliomas is associated with 5'CpG island methylation and unfavourable prognosis. J Cell Mol Med (2009) 1.01
The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma. Cell Mol Neurobiol (2011) 1.00
New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Int J Med Sci (2015) 1.00
Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res (2014) 1.00
Biology, genetics and imaging of glial cell tumours. Br J Radiol (2011) 1.00
Survival analysis of patients with high-grade gliomas based on data mining of imaging variables. AJNR Am J Neuroradiol (2012) 0.99
Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol (2013) 0.98
Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. Am J Surg Pathol (2012) 0.98
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. Onco Targets Ther (2013) 0.97
p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer. Genes Cancer (2011) 0.96
Aberrant signaling pathways in glioma. Cancers (Basel) (2011) 0.96
Emerging biomarkers in glioblastoma. Cancers (Basel) (2013) 0.96
Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas. BMC Cancer (2009) 0.95
IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol (2011) 0.95
Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. Trends Neurosci (2009) 0.95
A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano (2014) 0.95
BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas. J Transl Med (2013) 0.94
Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. Core Evid (2010) 0.94
Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Mol Cell Biol (2006) 0.94
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat (2005) 11.27
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol (2009) 6.43
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol (2005) 6.16
Epidemiology and etiology of gliomas. Acta Neuropathol (2005) 6.14
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Genome-wide association study identifies five loci associated with lung function. Nat Genet (2009) 4.10
The definition of primary and secondary glioblastoma. Clin Cancer Res (2012) 3.84
Integrity of the conduct of the IARC monographs program. Int J Occup Environ Health (2003) 3.55
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res (2009) 2.95
Reduced exposure to PM10 and attenuated age-related decline in lung function. N Engl J Med (2007) 2.86
Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci (2009) 2.75
Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol (2006) 2.51
Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology (2009) 2.44
BMP4-BMPR1A signaling in beta cells is required for and augments glucose-stimulated insulin secretion. Cell Metab (2007) 2.39
Gastric cancer in Japan--honing treatment, seeking causes. N Engl J Med (2008) 2.18
Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (2004) 2.15
Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys (2003) 2.10
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res (2003) 2.08
Recurrent intracranial aneurysms after successful neck clipping. World Neurosurg (2011) 2.03
The science and practice of carcinogen identification and evaluation. Environ Health Perspect (2004) 1.89
Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci (2008) 1.88
Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol (2008) 1.78
High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiol Biomarkers Prev (2004) 1.74
Neurogenic pulmonary edema in patients with subarachnoid hemorrhage. J Neurosurg Anesthesiol (2008) 1.74
Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet (2012) 1.68
Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS (2008) 1.66
ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res (2003) 1.64
A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg (2003) 1.60
Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS (2008) 1.60
Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat Genet (2011) 1.60
Occupation and larynx and hypopharynx cancer: a job-exposure matrix approach in an international case-control study in France, Italy, Spain and Switzerland. Cancer Causes Control (2003) 1.59
Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol (2004) 1.59
Follow-up of the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA 2) 1991-2003: methods and characterization of participants. Soz Praventivmed (2005) 1.55
Genome-wide joint meta-analysis of SNP and SNP-by-smoking interaction identifies novel loci for pulmonary function. PLoS Genet (2012) 1.52
Molecular classification of low-grade diffuse gliomas. Am J Pathol (2010) 1.51
TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol (2013) 1.51
Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res (2008) 1.45
Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? Biol Psychiatry (2006) 1.44
Mammography screening in Switzerland: limited evidence from limited data. Swiss Med Wkly (2004) 1.41
Genetic pathways to glioblastomas. Neuropathology (2005) 1.41
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. Mol Cancer Ther (2011) 1.39
Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol (2001) 1.38
Spontaneous otogenic intracerebral pneumocephalus: case report and review of the literature. Eur Arch Otorhinolaryngol (2004) 1.37
PTEN methylation and expression in glioblastomas. Acta Neuropathol (2003) 1.31
A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol (2009) 1.28
Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice. Am J Pathol (2003) 1.28
Molecular pathogenesis of astrocytic tumours. J Neurooncol (2004) 1.24
Association between ambient air pollution and diabetes mellitus in Europe and North America: systematic review and meta-analysis. Environ Health Perspect (2015) 1.24
PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol (2007) 1.23
Genome-wide association study of lung function decline in adults with and without asthma. J Allergy Clin Immunol (2012) 1.20
Overweight and obesity affect treatment response in major depression. Biol Psychiatry (2007) 1.18
Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol (2011) 1.18
Meat intake, cooking-related mutagens and risk of colorectal adenoma in a sigmoidoscopy-based case-control study. Carcinogenesis (2004) 1.16
Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. Hum Mol Genet (2012) 1.14
AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene (2003) 1.13
Long-term seizure outcomes following amygdalohippocampectomy. J Neurosurg (2003) 1.13
Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study. Nephrol Dial Transplant (2006) 1.13
A comprehensive evaluation of potential lung function associated genes in the SpiroMeta general population sample. PLoS One (2011) 1.13
Altered expression of immune defense genes in pilocytic astrocytomas. J Neuropathol Exp Neurol (2005) 1.11
Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res (2005) 1.09
Is age at menopause increasing across Europe? Results on age at menopause and determinants from two population-based studies. Menopause (2009) 1.09
Patterns of aneurysm recurrence. Neurosurgery (2013) 1.07
α₁-Antitrypsin level and pheno/genotypes. Chest (2013) 1.07
Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology (2009) 1.07
WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol (2007) 1.06
Glutathione S-transferase genotypes modify lung function decline in the general population: SAPALDIA cohort study. Respir Res (2007) 1.06
Noninvasive measurement of regional cerebral blood flow and regional cerebral blood volume by near-infrared spectroscopy and indocyanine green dye dilution. Neuroimage (2003) 1.04
Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int J Cancer (2010) 1.04
Fetal programming of pulmonary vascular dysfunction in mice: role of epigenetic mechanisms. Am J Physiol Heart Circ Physiol (2011) 1.04
Biobanking for epidemiological research and public health. Pathobiology (2007) 1.04
Association of genetic variants in the neurotrophic receptor-encoding gene NTRK2 and a lifetime history of suicide attempts in depressed patients. Arch Gen Psychiatry (2010) 1.02
Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol (2006) 1.01
Occupation and larynx and hypopharynx cancer: an international case-control study in France, Italy, Spain, and Switzerland. Cancer Causes Control (2003) 1.01
IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clin Cancer Res (2010) 1.01
Effect of high dose per pulse flattening filter-free beams on cancer cell survival. Radiother Oncol (2011) 1.01